1.
Tefferi A, Pardanani A, Gangat N. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. haematol [Internet]. 2023Nov.1 [cited 2024Jun.13];108(11):2919-32. Available from: https://haematologica.org/article/view/haematol.2022.282612